Teligent expects audit at injectables site

Teligent’s president and chief executive officer Jason Grenfell-Gardner says the firm anticipates a pre-approval inspection (PAI) by the US Food and Drug Administration (FDA) at its recently-expanded US manufacturing facility in Buena, New Jersey, in early 2019.

Teligent’s president and chief executive officer Jason Grenfell-Gardner says the firm anticipates a pre-approval inspection (PAI) by the US Food and Drug Administration (FDA) at its recently-expanded US manufacturing facility in Buena, New Jersey, in early 2019.

In an investors’ call detailing Teligent’s third-quarter results, Grenfell-Gardner stated that all construction had been completed at the facility and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business